



## Drug Discovery and Development: What We Have to Do Differently

### Program

Updated on 6/11/08

8:00 am - 5:00 pm	Exhibition
8:00 am - 8:55 am	Continental Breakfast & Registration
8:45 am - 9:00 am	<b>Welcome</b> Hui Li, Ph.D., President of SABPA SD, Senior Principal Scientist, Pfizer Global Research & Development
9:00 am - 10:30 am	<b>Session I. Innovative Approaches for Novel Medicines</b> Sui-Xiong Cai*, Ph.D., BOD of SABPA, Senior Director of Chemistry, EpiCept Corporation <b>Regulus Therapeutics: Pioneering A New Approach to Developing Therapeutics based on microRNAs</b> Kleanthis Xanthopoulos, Ph.D., President and CEO, Regulus Therapeutics <b>How to Use Nucleic Acids to Personalize Medicine</b> Charles Cantor, Ph.D., CSO, Sequenom <b>Using Protein Medicinal Chemistry to Create Science and Business Value</b> Stephen Kaldor, Ph.D. President and CEO, Ambrx
10:30 am - 10:50 am	<b>Coffee Break</b>
10:50 am - 12:00 pm	<b>Panel Discussion I: Evolving Business Models for Bio-Pharma R&amp;D - Challenges and Opportunities</b> Jack Lief*, Co-Founder, Chairman, President and CEO, Arena Stephen A. Bent*, Partner, Foley & Lardner Stan Fleming, M.B.A., Managing Member of Forward Ventures Troy Wilson, Ph.D., J.D. Co-Founder, President and CEO, Intellikine Dajun Yang, M.D., Ph.D., Managing Director, Morningside Group
12:00 pm – 12:15 pm	<b>San Diego Bio-Pharma Achievement Award (To Be Announced)</b> Hui Cai*, Ph.D., M.B.A., Chair of Board, SABPA, BOD of SDCA, Vice President of Corporate Development, HUYA Bioscience
12:15 pm - 1:30 pm	<b>Luncheon</b>
1:30 pm - 3:10 pm	<b>Session II. Future Strategies for Biomedical Research and Drug Discoveries</b> Ming Guo*, Ph.D., BOD of SABPA, Vice President, Pharmaceutical Sciences & Manufacturing, General Manager, Ascenta (Shanghai) R&D Center, Ascenta Therapeutics <b>Small Molecule Drug Discovery in the Modern World</b> Mike Varney, Ph.D., VP, Small Molecule Drug Discovery, Genentech <b>The Pfizer Incubator: Strategic Investment in Early-Stage Technologies</b> Mark J. Benedyk, Ph.D., Head of the Pfizer Incubator <b>Clinical and Translation Research in Singapore: Opportunities for Pharmaceutical, Biotechnology, and Academic Collaborations</b> Judith Swain, M.D., Executive Director, the Singapore Institute for Clinical Sciences Edward Holmes, M.D., Executive Deputy Chairman, Biomedical Research Council; Executive Chairman, National Medical Research Council, Singapore
3:10 pm - 3:30 pm	<b>Coffee Break</b>
3:30 pm - 4:30 pm	<b>Panel Discussion II: Business Opportunities in Beijing China</b> Wei Zhou*, Ph.D., J.D., Partner, Wilson Sonsini Goodrich & Rosati, P.C. <b>Beijing's economic image and investment environment</b> Weimin Zhou, M.B.A, Deputy Director of Beijing Investment Promotion Bureau <b>The current industrial development, potential market and the business opportunities</b> Xinxin Zhao, Deputy Director of Beijing Biotechnology Park <b>Speedy Generation of Antibodies for Proteomics &amp; Biomarker Discovery</b> Lei Sun, Ph.D. CEO and President, AbMax Biotechnology



## San Diego Bio-Pharma Conference 2008

The State Food and Drug Administration (SFDA), China

### **Closing**

4:30 pm

[Feng Tian](#), Ph.D.,, President of SDCA, BOD of SABPA, Scientific Investigator, Metabasis Therapeutics

4:30 pm - 5:00 pm

### **Networking**

\*Moderator